• 1
    Bosch FX, Lorincz A, Munoz N, Meijer CJ, Shah KV. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 2002; 55: 24465.
  • 2
    Parkin DM. The global health burden of infection-associated cancers in the year 2002. Int J Cancer 2006; 118: 303044.
  • 3
    Hildesheim A, Herrero R, Wachholder S, Rodriguez AC, Solomon D, Bratti MC, Schiller JT, Gonzales P, Dubin G, Porras C, Jilmenez SE, Lowy DR, et al. Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial. JAMA 2007; 298: 74353.
  • 4
    Rudlinger R, Smith IW, Bunney MH, Hunter JA. Human papillomavirus infections in a group of renal transplant recipients. Br J Dermatol 1986; 115: 68192.
  • 5
    Laga M, Icenogle JP, Marsella R, Manoka AT, Nzila N, Ryder RW, Vermund SH, Heyward WL, Nelson A, Reeves WC. Genital papillomavirus infection and cervical dysplasia—opportunistic complications of HIV infection. Int J Cancer 1992; 50: 458.
  • 6
    Sun XV, Kuhn L, Ellerberock RV, Chiasson MA, Bush TJ, Wright TC. Human papillomavirus infection in women infected with the human immunodeficiency virus. N Engl J Med 1997; 337: 13439.
  • 7
    Woo Y, Sterling JC, Damay I, Coleman N, Crawford R, Van der Burg SH, Stanley MA. Characterising the local immune responses in cervical intraepithelial neoplasia: a cross-sectional and longitudinal analysis. BJOG 2008; 115: 161621.
  • 8
    Cid-Arregui A. Therapeutic vaccines against human papillomavirus and cervical cancer. Open Virol J 2009; 3: 6783.
  • 9
    Kenter GG, Welters MJP, Valentijn ARPM, Lowik M, Berends-van der Meer DM, Vloon AP, Essahsah F, Fathers LM, Offringa R, Drijfhout JW, Wafelman AR, Oostendorp J, et al. Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasis. N Engl J Med 2009; 361: 183847.
  • 10
    Decrausaz L, Revaz V, Bobst M, Corthésy B, Romero P, Nardelli-Haefliger D. Induction of human papillomavirus oncogene-specific CD8 T cell effector responses in the genital mucosa of vaccinated mice. Int J Cancer 2010; 126: 246978.
  • 11
    Gallichan WS, Rosenthal KL. Long-term immunity and protection against herpes symplex virus type 2 in the murine female genital tract after mucosal but not systemic immunization. J Infect Dis 1998; 177: 115561.
  • 12
    Gupta S, Janani R, Bin Q, Luciw P, Greer CE, Perri S, Legg H, Donnelly J, Barnett S, O'Hagan D, Polo JM, Vajdy M. Characterization of human immunodeficiency virus gag-specific gamma interferon-expresing cells following protective mucosal immunization with alphavirus replicon particles. J Virol 2005; 79: 713545.
  • 13
    Jiang JQ, Patrick A, Moss RB, Rosenthal KL. CD8+ T-cell-mediated cross-clade protection in the genital tract following intranasal immunizaiton with inactivated human immunodeficiency virus antigen plus CpG oligodeoxynucleotides. J Virol 2005; 79: 393400.
  • 14
    Zhang X, Chentoufi AA, Dasgupta G, Nesburn AB, Wu M, Zhu X, Carpenter D, Wechsler SL, You S, BenMohamed L. A genital tract peptide epitope vaccine targeting TLR-2 efficiently induces local and systemic CD8+ T cells andprotects against herpes simplex virus type 2 challenge. Mucosal Immunol 2009; 2: 12943.
  • 15
    Lindqvist M, Persson J, Thörn K, Harandi AM. The mucosal adjuvant effect of alpha-galactosylceramide for induction of protective immunity to sexually transmitted viral infection. J Immunol 2009; 182: 643543.
  • 16
    Decrausaz L, Goncalves A-R, Domingos-Pereira S, Pythoud C, Stehle JC, Schiller J, Jichlinski P, Nardellihaefliger D. A novel mucosal orthotopic murine model of human papillomavrius-associated genital cancers. Int J Cancer 2010 Jul 15. [Epub ahead of print].
  • 17
    Balmelli C, Roden R, Potts A, Schiller J, De Grandi P, Nardelli-Haefliger D. Nasal immunization of mice with human papillomavirus type 16 virus-like particles elicits neutralizing antibodies in mucosal secretions. J Virol 1998; 72: 82209.
  • 18
    Balmelli C, Demotz S, Acha-Orbea H, De Grandi P, Nardelli-Haefliger D. Trachea, lung, and tracheobronchial lymph nodes are the major sites where antigen-presenting cells are detected after nasal vaccination of mice with human papillomavirus type 16 virus-like particles. J Virol 2002; 76: 12596602.
  • 19
    Fraillery D, Zosso N, Nardelli-Haefliger D. Rectal and vaginal immunization of mice with human papillomavirus L1 virus-like particles. Vaccine 2009; 27: 232634.
  • 20
    Gluck U, Gebbers JO, Gluck R. Phase I evaluation of intranasal virosomal influenza vaccine with and without Escherichia coli heat-labilre toxin in adult volunteers. J Virol 1999; 73: 77806.
  • 21
    Revaz V, Debonneville A, Bobst M, Nardelli-Haefliger D. Monitoring of vaccine-specific gamma interferon inductionin in genital mucosa of mice by real-time reverse-transcription-PCR. Clin Vaccine Immunol 2008; 5: 75764.
  • 22
    Labeur MS, Roters B, Pers B, Mehling A, Luger TA, Schwarz T, Grabbe S. Generation of tumor imunity by bone marrow-derived dendritic cells correlates with dendritic cell maturation stage. J Immunol 1999; 162: 16875.
  • 23
    Slade SJ, Langhorn J. Production of interferon-gamma during infection of mice with Plasmodium chabaudi chabaudi. Immunobiology 1989; 179: 35365.
  • 24
    Lin KY, Guarnieri FG, Staveleyocarroll KF, Levitsky HI, August JT, Pardoll DM, Wu TC. Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res 1996; 56: 216.
  • 25
    Neutra MR, Kozlowski PA. Mucosal vaccines: the promise and the challenge. Nat Rev Immunol 2006; 6: 14858.
  • 26
    Kaufman DR, Barouch DH. Translational mini-review series on vaccines for HIV: T lymphocyte trafficking and vaccine-elicited mucosal immunity. Clin Exp Immunol 2009; 157: 16573.
  • 27
    Belyakov IM, Ahlers JD. What role does the route of immunization play in the generation of protective immunity against mucosal pathogens? J Immunol 2009; 183: 688392.
  • 28
    Klinman DM, Currie D, Gursel I, Verthelyi D. Use of CpG oligodeosynucleotides as immune adjuvants. Immunol Rev 2004; 199: 20116.
  • 29
    Freytag LC, Clements JD. Mucosal adjuvants. Vaccine 2005; 23: 180413.
  • 30
    Kaufman DR, Bivas-Benita M, Simmons NL, Miller D, Barouch DH. Route of adenovirus-based HIV-1 vaccine delivery impacts the phenotype and trafficking of vaccine-elicited CD8+ T lymphocytes. J Virol 2010; 84: 598696.
  • 31
    Bivas-Benita M, Bar L, Gillard GO, Kaufman DR, Simmons NL, Hovav AH, Letvin NL. Efficient generation of mucosal and systemic antigen-specific CD8+ T-cell responses following pulmonary DNA immunization. J Virol 2010; 84: 576474.
  • 32
    Luci C, Hervouet C, Rousseau D, Holmgren J, Czerkinsky C, Anjuère F. Dendritic cell-mediated induction of mucosal cytotoxic responses following intravaginal immunization with the nontoxic B subunit of cholera toxin. J Immunol 2006; 176: 274957.
  • 33
    Cuburu N, Kweon MN, Hervouet C, Cha HR, Pang YY, Holmgren J, Stadler K, Schiller J, Anjuere F, Czerkinsky C. Sublingual immunization with nonreplicating antigens induces antibody-forming cells and cytotoxic T cells in the female genital tract mucosa and protects against genital papillomaviruc infection. J Immunol 2009; 183: 78519.
  • 34
    Manuri PR, Nehete B, Nehete PN, Reisenauer R, Wardell W, Courtney AN, Gambhira R, Lomada D, Chopra AK, Sastry KJ. Intranasal immunization with synthetic peptides corresponding to the E6 and E7 oncoproteins of human papillomavirus type 16 induces systemic and mucosal cellular immune responses and tumor protection. Vaccine 2007; 25: 330210.
  • 35
    Gherardi MM, Pérez-Jiménez E, Nàjera JL, Esteban M. Induction of HIV immunity in the genital tract after intranasal delivery of a MVA vector: enhanced immunogenicity after DNA prime-modified vaccinia virus Ankara boost immunization schedule. J Immunol 2004; 172: 620920.
  • 36
    Li Z, Zhang M, Zhou C, Zhao X, Iijima N, Frankel FR. Novel vaccination protocol with two live mucosal vectors elicits strong cell-mediated immunity in the vagina and protects against vaginal virus challenge. J Immunol 2008; 180: 250313.
  • 37
    Brandtzaeg P. Mucosal immunity: induction, dissemination and effector functions. Scand J Immunol 2009; 70: 50515.
  • 38
    Horton H, Russel N, Moore E, Baydo R, Havenar-Daughton C, Lee D, Deers M, Hudgens M, Weihold K, McElrath MJ. Correlation between interferon-γ secretion and cytotoxicity, in virus-psecific memory T cells. J Infect Dis 2004; 190: 16926.
  • 39
    Hussain S, Paterson Y. CD4+CD25+ regulatory T cells that secrete TGFβ and IL-10 are preferentially induced by a vaccine vector. J Immunother 2004; 27: 33946.
  • 40
    Zhou G, Drake CG, Levitsky HI. Amplification of tumor-specific regulatory T cells following therapeutic cancer vaccines. Blood 2006; 107: 62836.
  • 41
    Berraondo P, Nouzé C, Préville X, Leclerc C. Eradication of large tumors in mice by a tritherapy targetting the innate, adaptive and regulatory components of the immune system. Cancer Res 2007; 18: 884755.
  • 42
    Kang Y, Jin H, Zheng G, Du X, Xiao C, Zhang X, Geng S, Li X, Wang J, Chen A, Wang B. Co-inoculation of DNA and protein vaccines induces antigen-specific T cell suppression. Biochem Biophys Res Commun 2007; 23: 10349.
  • 43
    Daayana S, Elkord E, Winters U, Pawlita M, Roden R, Stern PL, Kitchener HC. Phase II trial of imiquimod and HPV therapeutic vaccination in patients with vulval intraepithelial neoplasia. Br J Cancer 2010; 102: 112936.
  • 44
    Oizumi S, Devey V, Yamazaki K, Schreiber T, Strbo N, Rosenblatt J, Podack ER. Surmounting tumor-induced immune suppression by frequent vaccination or immunization in the absence of B cells. J Immunother 2008; 31: 394401.
  • 45
    Schreiber TH, Deyev VV, Rosenblatt J, Podack ER. Tumor-induced suppression of CTL expansion and subjugation by gp96-Ig vaccination. Cancer Res 2009; 69: 202633.
  • 46
    McDermott MR, Goldsmith CH, Rosentahl DL, Brais LJ. T lymphocytes in genital lymph nodes protect mice from intravaginal infection with herpes simlex virus type 2. J Infect Dis 1989; 159: 4606.
  • 47
    Zhu Q, Thomson CW, Rosenthal KL, McDermott MR, Collins SM, Gauldie J. Immunization with adenovirus at the large intestinal mucosa as an effecive vaccination strategy against sexually transmitted viral infection. Mucosal Immunol 2008; 1: 7888.
  • 48
    Suvas PK, Dech HM, Sambira F, Zeng J, Onami TM. Systemic and mucosal infection program protective memory CD8 T cells in the vaginal mucosa. J Immunol 2007; 179: 81227.
  • 49
    Masopust D, Ahmed R. Reflections on CD8 T-cell activation and memory. Immunol Res 2004; 29: 15160.
  • 50
    Kim-Schulze S, Kim HS, Wainstein A, Kim DW, Yang WC, Moroziewicz D, Mong PY, Bereta M, Taback B, Wang Q, Kaufman HL. Intrarectal vaccination with recombinant vaccinia virus expressing carcinoembronic antigen induces mucosal and systemic immunity and prevents progression of colorectal cancer. J Immunol 2008; 181: 811219.